Literature DB >> 25299908

Gaucher's disease oral therapy gets nod from FDA.

Gunjan Sinha.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25299908     DOI: 10.1038/nbt1014-970

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN: 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  2 in total

1.  Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease.

Authors:  E Sidransky; M A Nalls; J O Aasly; J Aharon-Peretz; G Annesi; E R Barbosa; A Bar-Shira; D Berg; J Bras; A Brice; C-M Chen; L N Clark; C Condroyer; E V De Marco; A Dürr; M J Eblan; S Fahn; M J Farrer; H-C Fung; Z Gan-Or; T Gasser; R Gershoni-Baruch; N Giladi; A Griffith; T Gurevich; C Januario; P Kropp; A E Lang; G-J Lee-Chen; S Lesage; K Marder; I F Mata; A Mirelman; J Mitsui; I Mizuta; G Nicoletti; C Oliveira; R Ottman; A Orr-Urtreger; L V Pereira; A Quattrone; E Rogaeva; A Rolfs; H Rosenbaum; R Rozenberg; A Samii; T Samaddar; C Schulte; M Sharma; A Singleton; M Spitz; E-K Tan; N Tayebi; T Toda; A R Troiano; S Tsuji; M Wittstock; T G Wolfsberg; Y-R Wu; C P Zabetian; Y Zhao; S G Ziegler
Journal:  N Engl J Med       Date:  2009-10-22       Impact factor: 91.245

2.  Macrophage models of Gaucher disease for evaluating disease pathogenesis and candidate drugs.

Authors:  Elma Aflaki; Barbara K Stubblefield; Emerson Maniwang; Grisel Lopez; Nima Moaven; Ehud Goldin; Juan Marugan; Samarjit Patnaik; Amalia Dutra; Noel Southall; Wei Zheng; Nahid Tayebi; Ellen Sidransky
Journal:  Sci Transl Med       Date:  2014-06-11       Impact factor: 17.956

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.